

#700

RECEIVED

MAY 04 2000

Attorney Docket No.: 5709.200-U.S.

TECH CENTER 1600/2900 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: Svendsen et al.

Application No.: 09/441,313

Group Art Unit: 1632

Filed: November 16, 1999

Examiner: To be assigned

For: α -amylase variants

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith a reference which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.


While the reference may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the reference is "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no other material references than this listed exists or that a search has been conducted.

The reference is listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the reference is also enclosed. The reference is as follows:

1. WO 97/43424.

It is respectfully requested that this reference be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of



record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached reference.

The supplemental information disclosure statement submitted herewith is being filed before the mailing date of a first Office action on the merits. Therefore, no fee is due.

Date: April 24, 2000

Respectfully submitted,


A handwritten signature in cursive script, appearing to read "Elias J. Lambiris", written over a horizontal line.

Elias J. Lambiris, Reg. No. 33,728
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

Gp 1632



Attorney Docket No.: 5709.200-U.S.



PATENT

MAIL DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 04 2000

TECH CENTER 1600/2900

In re Application of: Svendsen et al.

Application No.: 09/441,313

Group Art Unit: 1632

Filed: November 16, 1999

Examiner: To be assigned

For: α -amylase variants

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Supplemental Information Disclosure Statement
2. Form PTO-1449
3. Copy of Reference

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner of Patents and Trademarks
Washington, DC 20231

on April 24, 2000.

Carol McFarlane
(name of person mailing paper)

Carol McFarlane
(signature of person mailing paper)